DE60110557D1 - Aminoadamantan-derivate als therapeutische mittel - Google Patents
Aminoadamantan-derivate als therapeutische mittelInfo
- Publication number
- DE60110557D1 DE60110557D1 DE60110557T DE60110557T DE60110557D1 DE 60110557 D1 DE60110557 D1 DE 60110557D1 DE 60110557 T DE60110557 T DE 60110557T DE 60110557 T DE60110557 T DE 60110557T DE 60110557 D1 DE60110557 D1 DE 60110557D1
- Authority
- DE
- Germany
- Prior art keywords
- derivatives
- disorders
- trauma
- neurological
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US510099 | 2000-02-22 | ||
US09/510,099 US6444702B1 (en) | 2000-02-22 | 2000-02-22 | Aminoadamantane derivatives as therapeutic agents |
PCT/US2001/005967 WO2001062706A1 (en) | 2000-02-22 | 2001-02-22 | Aminoadamantane derivatives as therapeutic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60110557D1 true DE60110557D1 (de) | 2005-06-09 |
DE60110557T2 DE60110557T2 (de) | 2006-04-27 |
Family
ID=24029379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60110557T Expired - Lifetime DE60110557T2 (de) | 2000-02-22 | 2001-02-22 | Aminoadamantan-derivate als therapeutische mittel |
Country Status (14)
Country | Link |
---|---|
US (5) | US6444702B1 (de) |
EP (2) | EP1259477B1 (de) |
JP (1) | JP4317343B2 (de) |
CN (1) | CN100339356C (de) |
AT (1) | ATE294774T1 (de) |
AU (2) | AU2001243271B2 (de) |
BR (1) | BR0108547A (de) |
CA (1) | CA2400916C (de) |
DE (1) | DE60110557T2 (de) |
ES (1) | ES2243468T3 (de) |
HK (1) | HK1052921A1 (de) |
MX (1) | MXPA02008170A (de) |
PT (1) | PT1259477E (de) |
WO (1) | WO2001062706A1 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6444702B1 (en) * | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
MXPA03005130A (es) * | 2000-12-07 | 2004-12-06 | Neuromolecular Inc | Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda. |
EP1852113A3 (de) * | 2000-12-07 | 2008-03-12 | Neuromolecular Inc. | Verfahren zur Behandlung neuropsychiatrischer Erkrankungen mit NMDA-Rezeptorantagonisten |
US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
JPWO2003068726A1 (ja) * | 2001-12-27 | 2005-06-02 | ダイセル化学工業株式会社 | 脂環式アミンのアミド誘導体とその製造法 |
WO2004037843A2 (en) * | 2002-10-25 | 2004-05-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments |
WO2004041555A1 (en) | 2002-11-01 | 2004-05-21 | Bridgestone/Firestone North American Tire, Llc | Method for designing tire noise pitch sequence |
WO2004050084A2 (en) * | 2002-11-29 | 2004-06-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Ace-inhibitors having antioxidant and nitricoxid-donor activity |
US20050124701A1 (en) * | 2003-06-11 | 2005-06-09 | Went Gregory T. | Method of targeting a therapeutic agent |
AR046314A1 (es) | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
CN100363329C (zh) * | 2004-01-09 | 2008-01-23 | 南京大学 | 合成美金刚胺盐酸盐的方法 |
WO2005072705A1 (en) * | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
ES2483126T3 (es) | 2004-06-17 | 2014-08-05 | Merz Pharma Gmbh & Co. Kgaa | Formulaciones de formas de dosificación de neramexano |
US20060002999A1 (en) | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
CA2569015A1 (en) * | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
US20080275112A1 (en) * | 2004-07-23 | 2008-11-06 | Schreiner Peter R | Invention Concerning Aminoadamantane Compounds |
US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
EP1827385B1 (de) | 2004-11-23 | 2013-03-27 | Adamas Pharmaceuticals, Inc. | Pharmazeutische zusammensetzung enthaltend memantin in verzögerter freisetzungs-form zur behandlung von dementia |
EP2623099A1 (de) | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Zusammensetzung und Verfahren zur Behandlung neurologischer Erkrankungen |
PL1874282T3 (pl) | 2005-04-06 | 2011-04-29 | Adamas Pharmaceuticals Inc | Sposoby i kompozycje do leczenia zaburzeń OUN |
US20080009546A1 (en) * | 2005-05-06 | 2008-01-10 | Chevron U.S.A. Inc. | Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders |
EP1885689A1 (de) * | 2005-05-06 | 2008-02-13 | Chevron U.S.A., Inc. | Diamondoidderivate mit therapeutischer wirkung |
CA2607600A1 (en) * | 2005-06-16 | 2006-12-28 | Forest Laboratories, Inc. | Modified and immediate release memantine bead formulation |
EP2040676A2 (de) * | 2006-07-06 | 2009-04-01 | Forest Laboratories, Inc. | Oral lösliche memantin-formulierungen |
CN101450911B (zh) * | 2007-11-30 | 2012-02-29 | 山东轩竹医药科技有限公司 | 被金刚烷取代的苯甲酸衍生物 |
WO2009151498A2 (en) * | 2008-03-28 | 2009-12-17 | Forest Laboratories Holdings Limited | Memantine formulations |
KR100998525B1 (ko) * | 2008-03-28 | 2010-12-07 | 나노다이아몬드 주식회사 | 아밀로이드 올리고머 독성 억제제로서의 아다만탄 유도체 |
EP3132793A1 (de) | 2009-12-02 | 2017-02-22 | Adamas Pharmaceuticals, Inc. | Amantadinzusammensetzungen und verfahren zur verwendung |
CN102241678B (zh) | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | 含有脂环结构化合物的抗肿瘤作用与应用 |
CN103833555B (zh) * | 2012-11-23 | 2016-12-21 | 上海京新生物医药有限公司 | 一种盐酸美金刚的制备方法 |
EP3485882A1 (de) | 2013-01-25 | 2019-05-22 | Case Western Reserve University | Zusammensetzungen zur behandlung von erkrankungen mit pervasiver entwicklung |
WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
CN105294450B (zh) * | 2014-05-29 | 2024-05-17 | 广州喜鹊医药有限公司 | 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用 |
US10800734B2 (en) | 2016-05-07 | 2020-10-13 | Sunshine Lake Pharma Co., Ltd. | Memantine compounds and their preparation and uses thereof |
US10214478B2 (en) * | 2016-11-28 | 2019-02-26 | Guangzhou Magpie Pharmaceuticals Co., Ltd. | Amantadine nitrate compounds with neural protective effect, and preparation and medical use thereof |
CN111356452A (zh) * | 2017-08-01 | 2020-06-30 | 斯图尔特·A·利普顿 | 用于治疗神经病况的方法和组合物 |
EP3713558A4 (de) * | 2017-11-22 | 2021-10-13 | Panorama Research Inc. | Aminoadamantylnitratverbindungen und ihre verwendung zur behandlung von zns-erkrankungen |
CN111662216A (zh) * | 2019-03-05 | 2020-09-15 | 广东东阳光药业有限公司 | 一种金刚烷胺类化合物的晶型及其制备方法 |
CN110938006A (zh) * | 2019-12-04 | 2020-03-31 | 重庆植恩药业有限公司 | 盐酸美金刚杂质c的制备方法 |
WO2021231582A1 (en) * | 2020-05-12 | 2021-11-18 | Eumentis Therapeutics, Inc. | Nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia |
CN117427057A (zh) * | 2022-07-14 | 2024-01-23 | 广州喜鹊医药有限公司 | 金刚烷硝酸酯类化合物在制备预防或治疗细胞因子风暴药物中的应用 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3328251A (en) | 1965-12-30 | 1967-06-27 | Du Pont | Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives |
US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
GB1175820A (en) | 1966-02-18 | 1969-12-23 | Upjohn Co | Amino-Adamantane Derivatives |
CA974518A (en) | 1972-04-20 | 1975-09-16 | Merz And Co. | Procedure for the manufacture of 1,3,5 trisubstituted adamantan compounds |
US4351847A (en) | 1981-06-26 | 1982-09-28 | Pennwalt Corporation | Antiviral alpha, alpha-dialkyl adamantylethylamines |
US4346112A (en) | 1981-06-29 | 1982-08-24 | University Patents Inc. | Composition and method for treating patients having Parkinson's Disease |
JPS584718A (ja) | 1981-06-30 | 1983-01-11 | Nippon Chibagaigii Kk | 新規適応症に用うる医薬製剤 |
WO1990011761A1 (en) | 1989-03-31 | 1990-10-18 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
US5506231A (en) | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
US5334618A (en) | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
ATE94384T1 (de) | 1989-04-14 | 1993-10-15 | Merz & Co Gmbh & Co | Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie. |
WO1991002810A1 (en) | 1989-08-09 | 1991-03-07 | The Children's Medical Center Corporation | Nmda oxidizing agents for protecting neurons from injury |
US5091391A (en) | 1990-08-16 | 1992-02-25 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of resisting neurodegenerative disorders |
US5455279A (en) | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
US6071876A (en) | 1991-04-19 | 2000-06-06 | Children's Medical Center Corporation | Method of preventing NMDA receptor complex-mediated neuronal damage |
JPH06506690A (ja) | 1991-04-19 | 1994-07-28 | ザ チルドレンズメディカルセンター コーポレーション | Nmda受容体複合体に媒体されるニューロン障害の阻止方法 |
DE4225730C2 (de) | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
JPH06161125A (ja) | 1992-11-17 | 1994-06-07 | Mita Ind Co Ltd | 電子写真感光体 |
US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
US5677349A (en) * | 1995-04-27 | 1997-10-14 | Gilad; Gad M. | Agmatine for the treatment of neurotrauma and neurodegenerative diseases |
DE19528388A1 (de) * | 1995-08-02 | 1997-02-06 | Hans Peter Prof Dr Med Zenner | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs |
DE19531342B4 (de) | 1995-08-25 | 2007-11-29 | Merz Pharma Gmbh & Co. Kgaa | Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren |
ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
US5776935A (en) | 1996-07-25 | 1998-07-07 | Merz & Co. Gmbh & Co. | Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission |
EP1574495A1 (de) * | 1997-01-14 | 2005-09-14 | Daicel Chemical Industries, Ltd. | Adamantanderivate |
WO1998040337A1 (fr) | 1997-03-11 | 1998-09-17 | Daicel Chemical Industries, Ltd. | Derives d'adamantane et procede de production associe |
ES2175614T3 (es) | 1997-04-10 | 2002-11-16 | Pfizer | Derivados fluorosustituidos de adamantano. |
US6071966A (en) | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
DK1009732T3 (da) | 1997-06-30 | 2003-09-22 | Merz Pharma Gmbh & Co Kgaa | 1-Amino-alkylcyclohexan NMDA receptor antagonister |
MA26553A1 (fr) | 1997-10-17 | 2004-12-20 | Centaur Pharmaceuticals Inc | Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la |
GB9726388D0 (en) | 1997-12-12 | 1998-02-11 | Cerebrus Ltd | Chemical compounds |
WO1999037149A1 (en) | 1998-01-27 | 1999-07-29 | Brigham & Women's Hospital | Methods of treating cytotoxic damage |
JP4626896B2 (ja) * | 1998-02-13 | 2011-02-09 | ダイセル化学工業株式会社 | アシル化剤とそれを用いたアシル化法、及びアダマンタン誘導体 |
JP4215858B2 (ja) | 1998-04-21 | 2009-01-28 | ダイセル化学工業株式会社 | アダマンタノール誘導体及びその製造法 |
EP0990632A4 (de) * | 1998-04-21 | 2004-04-14 | Daicel Chem | Adamantanmethanol-derivate und verfahren zu ihrer herstellung |
US6482854B1 (en) | 1999-03-25 | 2002-11-19 | Massachusetts Eye And Ear Infirmary | Glaucoma treatment |
US7589167B2 (en) | 2000-02-22 | 2009-09-15 | J. David Gladstone Institutes | ZA loops of bromodomains |
US6444702B1 (en) * | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
US20040009613A1 (en) | 2001-02-16 | 2004-01-15 | Ming-Ming Zhou | Methods of identifying modulators of bromodomains |
US6602862B1 (en) | 2000-09-19 | 2003-08-05 | Merz Pharma Gmbh & Co., Kgaa | 1-Amino-alkylcyclohexanes as trypanocidal agents |
MXPA03005130A (es) | 2000-12-07 | 2004-12-06 | Neuromolecular Inc | Metodos para tratar trastornos neurosiquiatricos con antagonistas del receptor del nmda. |
US20040122090A1 (en) | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
EP1389181A4 (de) | 2001-04-02 | 2005-10-19 | Panorama Res Inc | Nitroxid- und nitron-antioxidationsmittel als therapeutika |
JP2003137842A (ja) | 2001-10-29 | 2003-05-14 | Tosoh Corp | α−フルオロアルキル−2−アダマンチルアクリレート類及びその製造方法 |
JP2003137841A (ja) | 2001-10-29 | 2003-05-14 | Tosoh Corp | α−フルオロアルキル−1−アダマンチルアクリレート類及びその製造方法 |
-
2000
- 2000-02-22 US US09/510,099 patent/US6444702B1/en not_active Expired - Lifetime
-
2001
- 2001-02-22 BR BR0108547-6A patent/BR0108547A/pt not_active Application Discontinuation
- 2001-02-22 JP JP2001561716A patent/JP4317343B2/ja not_active Expired - Fee Related
- 2001-02-22 DE DE60110557T patent/DE60110557T2/de not_active Expired - Lifetime
- 2001-02-22 CA CA2400916A patent/CA2400916C/en not_active Expired - Fee Related
- 2001-02-22 EP EP01916217A patent/EP1259477B1/de not_active Expired - Lifetime
- 2001-02-22 PT PT01916217T patent/PT1259477E/pt unknown
- 2001-02-22 MX MXPA02008170A patent/MXPA02008170A/es active IP Right Grant
- 2001-02-22 EP EP05009660A patent/EP1568685A1/de not_active Ceased
- 2001-02-22 WO PCT/US2001/005967 patent/WO2001062706A1/en active Application Filing
- 2001-02-22 CN CNB018068928A patent/CN100339356C/zh not_active Expired - Fee Related
- 2001-02-22 AU AU2001243271A patent/AU2001243271B2/en not_active Ceased
- 2001-02-22 AT AT01916217T patent/ATE294774T1/de not_active IP Right Cessation
- 2001-02-22 ES ES01916217T patent/ES2243468T3/es not_active Expired - Lifetime
- 2001-02-22 AU AU4327101A patent/AU4327101A/xx active Pending
-
2002
- 2002-07-19 US US10/199,156 patent/US6620845B2/en not_active Expired - Fee Related
-
2003
- 2003-05-27 HK HK03103751A patent/HK1052921A1/xx not_active IP Right Cessation
- 2003-08-04 US US10/634,069 patent/US20040029929A1/en not_active Abandoned
-
2005
- 2005-11-17 US US11/283,241 patent/US7326730B2/en not_active Expired - Lifetime
-
2008
- 2008-02-04 US US12/025,622 patent/US20080183003A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6444702B1 (en) | 2002-09-03 |
CN1446193A (zh) | 2003-10-01 |
JP4317343B2 (ja) | 2009-08-19 |
MXPA02008170A (es) | 2005-07-01 |
CA2400916A1 (en) | 2001-08-30 |
DE60110557T2 (de) | 2006-04-27 |
BR0108547A (pt) | 2003-06-10 |
AU4327101A (en) | 2001-09-03 |
US20060106222A1 (en) | 2006-05-18 |
ATE294774T1 (de) | 2005-05-15 |
US20030008889A1 (en) | 2003-01-09 |
EP1568685A1 (de) | 2005-08-31 |
EP1259477B1 (de) | 2005-05-04 |
EP1259477A1 (de) | 2002-11-27 |
PT1259477E (pt) | 2005-08-31 |
HK1052921A1 (en) | 2003-10-03 |
US20080183003A1 (en) | 2008-07-31 |
US6620845B2 (en) | 2003-09-16 |
US7326730B2 (en) | 2008-02-05 |
CA2400916C (en) | 2012-07-10 |
WO2001062706A1 (en) | 2001-08-30 |
ES2243468T3 (es) | 2005-12-01 |
US20040029929A1 (en) | 2004-02-12 |
CN100339356C (zh) | 2007-09-26 |
JP2003523989A (ja) | 2003-08-12 |
AU2001243271B2 (en) | 2004-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE294774T1 (de) | Aminoadamantan-derivate als therapeutische mittel | |
HK1008980A1 (en) | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders | |
HUP9904525A2 (hu) | S-(-)-N-Propargil-1-amino-indán tartalmú neurológiai rendellenességek kezelésére alkalmas gyógyszerkészítmények | |
TW200635589A (en) | Therapeutic agents | |
TW200745135A (en) | Therapeutic agents | |
DE60142236D1 (de) | Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung | |
HK1036792A1 (en) | Fluorine-containing amino acid derivatives. | |
TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
HUP9802862A2 (hu) | (1S,2S)-1-(4-hydroxi-fenil)-2-(4-hidroxi-4-fenil-1-piperidinil)-1-propanol-metánszulfonát-trihidrát, és ezt a vegyületet tartalmazó a központi idegrendszeri rendellenességek kezelésére alkalmas gyógyászati készítmények | |
ZA972496B (en) | Substituted 2,3-benzodiazepin-4-ones and the use thereof. | |
NO961435L (no) | Terapeutiske midler | |
MXPA02010231A (es) | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. | |
ATE504310T1 (de) | Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c | |
WO2005046605A3 (en) | Compositions and methods of treating neurological diseases | |
WO2007106862A3 (en) | The use of statins to stimulate neurogenesis | |
RU2003102437A (ru) | 7-гидроксиэпиандростерон, обладающий нейропротективной активностью | |
WO2002076437A3 (en) | Methods for treating neurodegenerative diseases including alzheimer's | |
WO2005095361A8 (en) | Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders | |
MXPA01009384A (es) | Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina. | |
DE60004835D1 (de) | 7-oxo-2-azabicyclo[2.2.1]heptane als selektive muskarin-rezeptor antagonisten | |
DE60209192D1 (de) | Inhibitore der Verzweigte-Aminosäure-abhängigen Aminotransferase und deren Verwendung in der Behandlung von Neurodegenerativen Erkrankungen | |
DE60313643D1 (de) | N-acetyl-l-pipecolic säure als promoter der produktion des neurotrophischen faktors | |
WO2023107630A3 (en) | Amino alcohol compounds and uses thereof | |
MX9709911A (es) | Compuestos activos en un sitio novedoso en canales de calcio operados por receptor utiles para el tratamiento de trastornos neurologicos. | |
CA2257234A1 (en) | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |